Myxoid/round cell liposarcoma

disease

On this page

Also known as MRCLSmyxoid/round-cell liposarcoma

Summary

Myxoid/round cell liposarcoma (MONDO:0020561) is a disease and 5 clinical trials. Top therapeutic interventions include atezolizumab and ny-eso-1. A subtype of liposarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
Phenotypes (HPO): 3
Clinical trials: 5

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.1	Europe	Validated

Signs & symptoms

Clinical features (HPO)

3 HPO clinical features (Orphanet curated; top 3 by frequency):

HPO ID	Term	Frequency
HP:0001482	Subcutaneous nodule	Very frequent (80-99%)
HP:0002027	Abdominal pain	Occasional (5-29%)
HP:0002579	Gastrointestinal dysmotility	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	myxoid/round cell liposarcoma
Mondo ID	MONDO:0020561
Orphanet	99967
UMLS	C0545074
MedGen	107784
GARD	0007157
Is cancer (heuristic)	no

Also known as: MRCLS · myxoid/round-cell liposarcoma

Data availability: 13 cell lines.

Disease family

This is a subtype of liposarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › lipomatous cancer › liposarcoma › myxoid/round cell liposarcoma

Subtypes (2): round cell liposarcoma, myxoid liposarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	3
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05120271	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
NCT02609984	PHASE2	TERMINATED	Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
NCT06083883	PHASE1	RECRUITING	Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
NCT02059850	PHASE1	WITHDRAWN	NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
NCT03399448	PHASE1	TERMINATED	NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ATEZOLIZUMAB	4	1
NY-ESO-1	2	1

Drugs: Atezolizumab